Dateline City:
WHITEHOUSE STATION, N.J.
Phase II/III Trial of MK-3475 in Patients with NSCLC Currently Enrolling
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the presentation of interim data from a Phase 1B trial
(PN001) evaluating MK-3475, an investigational anti-PD-1 immunotherapy,
in patients with previously-treated non-small cell lung cancer (NSCLC).
The data were presented today by Dr.
Language:
English
Contact:
MerckMedia Contacts:Ian McConnell, 908-423-3046orClaire Mulhearn, 908-423-7425orInvestor Contacts:Carol Ferguson, 908-500-1101orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more